Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Sell
13
LFST Quote, Financials, Valuation and Earnings
Last price:
$5.84
Seasonality move
:
-1.53%
Day range:
$5.79 - $5.90
52-week range:
$4.64 - $8.61
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.73x
P/B ratio:
1.56x
Volume:
1M
Avg. volume:
1.7M
1-year change:
-20.97%
Market cap:
$2.3B
Revenue:
$1.3B
EPS (TTM):
-$0.10
Analysts' Opinion
-
Consensus RatingLifeStance Health Group has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.86, LifeStance Health Group has an estimated upside of 51.66% from its current price of $5.84.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $5.84.
Fair Value
-
According to the consensus of 6 analysts, LifeStance Health Group has 51.66% upside to fair value with a price target of $8.86 per share.
LFST vs. S&P 500
-
Over the past 5 trading days, LifeStance Health Group has underperformed the S&P 500 by -1.36% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
LifeStance Health Group does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
LifeStance Health Group has grown year-over-year revenues for 0 quarters straight. In the most recent quarter LifeStance Health Group reported revenues of $333M.
Earnings Growth
-
LifeStance Health Group has grown year-over-year earnings for 0 quarters straight. In the most recent quarter LifeStance Health Group reported earnings per share of --.
Enterprise value:
2.4B
EV / Invested capital:
1.39x
Price / LTM sales:
1.73x
EV / EBIT:
--
EV / Revenue:
1.88x
PEG ratio (5yr expected):
--
EV / Free cash flow:
23.57x
Price / Operating cash flow:
21.73x
Enterprise value / EBITDA:
50.80x
Gross Profit (TTM):
$417.5M
Return On Assets:
-1.69%
Net Income Margin (TTM):
-2.78%
Return On Equity:
-2.48%
Return On Invested Capital:
-2.07%
Operating Margin:
0.48%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $909M | $1.1B | $1.3B | $300.4M | $333M | |
| Gross Profit | $252.4M | $327.2M | $417.5M | $94.7M | $109.8M | |
| Operating Income | -$179.4M | -$171.8M | -$13.2M | -$16.8M | $1.6M | |
| EBITDA | -$107.8M | -$83.1M | $47.5M | $7.7M | $15.4M | |
| Diluted EPS | -$0.52 | -$0.48 | -$0.10 | -$0.06 | -- | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $109.6M | $263.3M | $212.5M | $244.1M | $304.6M | |
| Total Assets | $1.6B | $2B | $2.2B | $2.1B | $2.1B | |
| Current Liabilities | $96.8M | $125.6M | $181.1M | $207.5M | $207.4M | |
| Total Liabilities | $652.3M | $415.9M | $653.4M | $677.3M | $647.6M | |
| Total Equity | $954M | $1.5B | $1.5B | $1.4B | $1.5B | |
| Total Debt | $387.3M | $177.4M | $224.8M | $279.9M | $276.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $41.6M | -$30.8M | $126M | -$21.8M | -$3.1M | |
| Cash From Investing | -$116.2M | -$37.9M | -$23.6M | -$5.1M | -$7.2M | |
| Cash From Financing | $28.9M | $49.9M | -$17.5M | -$2.4M | -$10M | |
| Free Cash Flow | -$17.5M | -$68.7M | $102.4M | -$26.9M | -$10.3M | |
LFST
Sector
Market Cap
$2.3B
$34.2M
Price % of 52-Week High
67.83%
43.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
-20.97%
-41.71%
Beta (5-Year)
--
0.657
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$5.81
200-day SMA
Sell
Level
$6.97
Bollinger Bands (100)
Sell
Level
6.44 - 7.9
Chaikin Money Flow
Buy
Level
1.4M
20-day SMA
Sell
Level
$6.18
Relative Strength Index (RSI14)
Sell
Level
38.68
ADX Line
Sell
Level
26.99
Williams %R
Neutral
Level
-69.4915
50-day SMA
Sell
Level
$6.54
MACD (12, 26)
Sell
Level
-0.25
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Sell
Level
-19.6M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.5672)
Buy
CA Score
(Annual)
Level (0.5271)
Buy
Beneish M-Score
(Annual)
Level (-2.8245)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (0.4512)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
Stock Forecast FAQ
In the current month, LFST has received 4 Buy ratings 2 Hold ratings, and 0 Sell ratings. The LFST average analyst price target in the past 3 months is $8.86.
-
Where Will LifeStance Health Group Stock Be In 1 Year?
According to analysts, the consensus estimate is that LifeStance Health Group share price will rise to $8.86 per share over the next 12 months.
-
What Do Analysts Say About LifeStance Health Group?
Analysts are divided on their view about LifeStance Health Group share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that LifeStance Health Group is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is LifeStance Health Group's Price Target?
The price target for LifeStance Health Group over the next 1-year time period is forecast to be $8.86 according to 6 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is LFST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for LifeStance Health Group is a Buy. 4 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LFST?
You can purchase shares of LifeStance Health Group via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase LifeStance Health Group shares.
-
What Is The LifeStance Health Group Share Price Today?
LifeStance Health Group was last trading at $5.84 per share. This represents the most recent stock quote for LifeStance Health Group. Yesterday, LifeStance Health Group closed at $5.84 per share.
-
How To Buy LifeStance Health Group Stock Online?
In order to purchase LifeStance Health Group stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Mobileye Might Be Wall Street’s Next Big Surprise
The trend to automate vehicles started long ago when adding…
Why Is Rigetti Stock Going Up?
Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
99
SOC alert for May 20
Sable Offshore [SOC] is down 0.79% over the past day.
Buy
52
RGC alert for May 20
Regencell Bioscience Holdings [RGC] is up 31.16% over the past day.
Sell
40
GWLIF alert for May 20
Great-West Lifeco [GWLIF] is up 13.42% over the past day.
